Q BioMed plans to accelerate up to four more assets

February 9, 2017 Christoph Graener

Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking to add three to four more assets to its portfolio. Company founder and CEO, Denis Corin, outlines to Mike Ward, Informa Pharma Intelligence’s insights global director of content, the progress Q BioMed has made with its first two assets and details his ambition to expand further in the coming two to three years.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Denis Corin – CEO and Chairman, Q Biomed Inc.

Previous Article
Advancing neurokinin receptor antagonists in respiratory and women’s health

Starting the year with a cash injection of GDP 23 million, NeRRe Therapeutics intends to advance its neurok...

Next Article
AmpliPhi advances phage in clinic to address microbial infections

AmpliPhi CEO Scott Salka explains how he is looking to secure sufficient capital to support the Phase II de...